Interleukin-10 in Cancer Immunotherapy: From Bench to Bedside

Authors

Mohamad Adham Salkeni
Aung Naing

Publication Date

9-1-2023

Journal

Trends Cancer

Abstract

Interleukin (IL)-10 was one of the first cytokines to be recognized. However, its functionality in promoting antitumor immunity was described more recently. Context- and concentration-dependent biological effects are the hallmarks of the pleiotropic role of IL-10. Despite reducing tumor-promoting inflammation, IL-10 may have a role in rejuvenating exhausted tumor-resident T cells. Contrary to the assumption that IL-10 produces an immunosuppressive tumor microenvironment (TME), it promotes activation of tumor-resident CD8+ T cells, which aids tumor rejection. Emerging data from published early-Phase trials have shown mixed results in different tumor types. In this review, we summarize the biological effects of IL-10 and highlight the clinical experience using pegilodecakin.

Keywords

Humans, Interleukin-10, Neoplasms, Cytokines, Immunotherapy, Tumor Microenvironment, T cell, cancer, inflammation, interleukin 10, pegilodecakin, pegylated IL-10

Comments

PMID: 37321942